

# 個人簡歷



<b>Position</b>	副教授
<b>Gender</b>	男
<b>Contact number</b>	+853-88973539
<b>E-mail address</b>	xxfan@must.edu.mo
<b>Faculty</b>	中藥質量研究國家重點實驗室，澳門科技大學

## 1. 個人簡介

范星星，男，博士。現為澳門科技大學中藥質量研究國家重點實驗室副教授；中國食品藥品安全促進會細胞治療分會常務理事；SCI 雜誌； *Biochemistry and Biophysics Reports* 執行主編， *Pharmacological Research* 副主編和 *Frontiers in immunology* 的客座編輯。主要研究方向包括：（1）炎症和腫瘤免疫治療；（2）中藥免疫藥理學；（3）抗腫瘤（*EGFR/KRAS*）靶向藥物開發。曾主持或參與多項澳門科技發展基金項目，已在抗炎抗腫瘤領域發表高影響力 SCI 文章百餘篇，包括有 *Coordination Chemistry Reviews*、*Nano-micro Letters*、*Nature communications*、*BMC medicine*、*Pharmacol Ther*、*Antioxid Redox Signal*、*Cell Death Dis* 等雜誌。獲批國際專利十餘項，2018 年曾參獲教育部自然科學一等獎。

## 2. 教學科目

基礎藥理學、解剖生理學、中藥藥理學實驗方法等

## 3、研究方向

抗炎抗腫瘤免疫調控藥物的開發

（1）小分子靶向藥物開發。腫瘤新型靶向藥物開發，包括腫瘤特異性靶點抑制劑及免疫調控靶點的激動劑篩選。

(2) 腫瘤細胞免疫治療。研製開發多款 SCFV 和細胞因子嵌合型 CAR 表達載體，可有效清除免疫抑制性細胞，並啟動機體免疫，進而實現提高免疫治療療效的目的。

#### 4. 研究經驗/工作經歷

2023-至今                      澳門科技大學中藥質量研究國家重點實驗室，副教授  
2017-2023                      澳門科技大學中藥質量研究國家重點實驗室，助理教授

#### 5. 代表性文章

➤ ***Corresponding author\* or First author#***

- (1) Depletion of regulatory T cells enhancing the anti-tumor effect of in situ vaccination in solid tumors. *Pharmacol Res.* Volume 203, May 2024, 107174. **IF=9.3**
- (2) Longitudinal high-dimensional analysis identifies biomarkers of response to anti-PD-1 immunotherapy. *Nature Communications.* 2023 Aug 22;14(1):5115. **IF=17.7**
- (3) Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor. *Vaccines* (Basel). 2023 Feb; 11(2): 394. **IF=7.8.**
- (4) Tumor PKC $\delta$  instigates immune exclusion in EGFR-mutated non-small cell lung cancer. *BMC Medicine.* volume 20, Article number: 470 (2022). **IF=11.806.**
- (5) Holistic immunomodulation for small cell lung cancer. *Seminars in cancer biology.* 2022 Dec 2; S1044-579X (22)00245-0. **IF= 17.012.**
- (6) Bacteria-based nanodrug for anticancer therapy. *Pharmacological Research.* 106282. **IF= 10.330.**
- (7) PA-MSHA Induces Inflamed Tumor Microenvironment and Sensitizes Tumor to Anti-PD-1 Therapy, *Cell Death & Disease.* 2022 Nov 7;13(11):931. **IF= 9.685.**
- (8) Chelerythrine ameliorates rheumatoid arthritis by modulating the AMPK/mTOR/ULK-1 signaling pathway. *Phytomedicine.* 154140. **IF= 6.65.**
- (9) Decoding Lung Cancer at Single-Cell Level. *Front Immunol.* 2022; 13: 883758. **IF= 8.786.**
- (10) Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor, *Pharmacological Research.* 106454. **IF= 10.330.**
- (11) Low-dimensional nanomaterials enabled autoimmune disease treatments: Recent advances, strategies, and future challenges. *Coordination Chemistry Reviews.* 2020, 213697. **IF= 22.367.**
- (12) ROS-Responsive Berberine Polymeric Micelles Effectively Suppressed the Inflammation of Rheumatoid Arthritis by Targeting Mitochondria. *Nano-Micro Letters.* volume 12, Article number: 76 (2020). **IF=16.264.**

➤ **Representative Papers published as Co-author**

- (1) Ying Xie, Wei-Yu Meng, Run-Ze Li, Yu-Wei Wang, Xin Qian, Chang Chan, Zhi-Fang Yu, Xing-Xing Fan, Mei-Fang Wang, Elaine Lai-Han Leung. Early lung cancer diagnostic biomarker discovery by machine learning methods. *Transl Oncol*. 2021 Jan;14(1):100907. IF=4.010.
- (2) Ze-Bo Jiang, Ju-Min Huang, Ya-Jia Xie, Wenjun Wang, Xiao-Jun Yao, Xing-Xing Fan, Qi-Biao Wu, Chun Xie, Mei-Fang Wang, Elaine Lai-Han Leung. Evodiamine suppresses non-small cell lung cancer by elevating CD8+T cells and downregulating the MUC1-C/PD-L1 axis. *J Exp Clin Cancer Res*. 2020 Nov 19;39(1):249. IF=11.161.
- (3) Elaine Lai-Han Leung, Hu-Dan Pan, Yu-Feng Huang, Xing-Xing Fan, Wan-Ying Wang, Fang He, Jun Cai, Hua Zhou, Liang Liu. The Scientific Foundation of Chinese Herbal Medicine against COVID-19. *Engineering (Beijing)*. 2020 Oct;6(10):1099-1107. IF=7.553.
- (4) Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Elaine Lai-Han Leung, Mei-Fang Wang. Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. *J Cancer Res Clin Oncol*. 2020 Jun;146(6):1441-1450. IF=4.553.
- (5) Masayuki Wada, Hongyu Zhang, Liu Fang, Jia Feng, Charlotte Olivia Tse, Wenli Zhang, Qi Chen, Xing-Xing Fan, Xun Jiang, Yupo Ma. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies. *Stem Cell Rev Rep*. 2020 Apr;16(2):369-384. IF=5.739.
- (6) Lulu E Yan, Hongyu Zhang, Masayuki Wada, Liu Fang, Jia Feng, Lai-Han Leung, Xing-Xing Fan, Lisa Senzel, Xun Jiang, Yupo Ma, William Tse. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy. *Stem Cell Rev Rep*. 2020 Apr;16(2):385-396. IF=5.739.
- (7) Yuwei Wang, Qianqian Wang, Xing-Xing Fan, Qi Biao Wu, Elaine Lai-Han Leung, Yang Ye, Xiaojun Yao. Discovery of a novel protein kinase C activator from *Croton tiglium* for inhibition of non-small cell lung cancer. *Phytomedicine*. 2019 Dec; 65:153100. IF=4.268.
- (8) Fu-Gang Duan, Mei-Fang Wang, Ya-Bing Cao, Dan Li, Run-Ze Li, Xing-Xing Fan, Imran Khan, Huan-Ling Lai, Yi-Zhong Zhang, Liang Liu, Yi-Jun Tang, Elaine Lai-Han Leung. MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer. *Cell Death Dis*. 2019 Oct 28;10(11):821. IF=6.304.
- (9) Elaine Lai-Han Leung, Lian Xiang Luo, Ying Li, Zhong-Qiu Liu, Lan Lan Li, Dan Feng Shi, Ying Xie, Min Huang, Lin Lin Lu, Fu Gang Duan, Ju Min Huang, Xing-Xing Fan, Zhong Wen Yuan, Jian Ding, Xiao Jun Yao, David C Ward, Liang Liu. Identification of a new inhibitor of KRAS-PDE $\delta$  interaction targeting KRAS mutant non-small cell lung

- cancer. *Int J Cancer*. 2019 Sep 1;145(5):1334-1345. IF=4.757.
- (10) Yize Zhang, Chae Young Han, Fu Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Robin J Parks, Yi-Jun Tang, Mei-Fang Wang, Liang Liu, Benjamin K Tsang, Elaine Lai-Han Leung. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. *Cancer Cell Int*. 2019 Jul 19; 19:188. IF=4.175.
- (11) Run-Ze Li, Xing-Xing Fan, Dan-Feng Shi, Guo-Yuan Zhu, Yu-Wei Wang, Lian-Xiang Luo, Hu-Dan Pan, Xiao-Jun Yao, Elaine Lai-Han Leung, Liang Liu. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC). *Chem Biol Drug Des*. 2018 Nov;92(5):1851-1858. IF=2.584.
- (12) Elaine Lai Han Leung, Lian Xiang Luo, Zhong Qiu Liu, Vincent Kam Wai Wong, Lin Lin Lu, Ying Xie, Ni Zhang, Yuan Qing Qu, Xing-Xing Fan, Ying Li, Min Huang, Dai Kai Xiao, Jun Huang, Yan Ling Zhou, Jian Xing He, Jian Ding, Xiao Jun Yao, David C Ward, Liang Liu. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. *Cell Death Dis*. 2018 Feb 13;9(2):216. IF=6.340.
- (13) Chun Xie, Ying Li, Lan-Lan Li, Xing-Xing Fan, Yu-Wei Wang, Chun-Li Wei, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. *Front Pharmacol*. 2017 Nov 14; 8:823. IF=4.225.
- (14) Lian-Xiang Luo, Ying Li, Zhong-Qiu Liu, Xing-Xing Fan, Fu-Gang Duan, Run-Ze Li, Xiao-Jun Yao, Elaine Lai-Han Leung, Liang Liu. Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. *Front Pharmacol*. 2017 Apr 11; 8:199. IF=4.225.
- (15) Lian-Xiang Luo, Xing-Xing Fan, Ying Li, Xia Peng, Yin-Chun Ji, Wendy Wen-Luan Hsiao, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao. Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells. *Medchemcomm*. 2017 Jan 26;8(3):621-624. IF=2.807.
- (16) Su-Wei Xu, Betty Yuen Kwan Law, Simon Wing Fai Mok, Elaine Lai Han Leung, Xing-Xing Fan, Paolo Saul Coghi, Wu Zeng, Chung-Hang Leung, Liang Liu, Vincent Kam Wai Wong. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. *Int J Oncol*. 2016 Oct;49(4):1576-88. IF=3.899.
- (17) Ze-Bo Jiang, Jun Huang, Chun Xie, Xia Li, Liping Liu, Jiayi He, Hui Pan, Liyan Huang, Xing-Xing Fan, Xiao-Jun Yao, Ying Xie, Na Li, Liang Liu, Jian-Xing He, Elaine Lai-Han Leung. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. *Oncol Rep*. 2016 Jul;36(1):365-75. IF=3.417.
- (18) Yi-Ze Zhang, Xi Chen, Xing-Xing Fan, Jian-Xing He, Jun Huang, Da-Kai Xiao, Yan-Ling Zhou, Sen-You Zheng, Jia-Hui Xu, Xiao-Jun Yao, Liang Liu, Elaine Lai-Han Leung.

Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of  $\alpha$ -Tubulin and Inhibition of Microtubule Formation. *Molecules*. 2016 Mar 18;21(3):374. IF=3.267.

(19) Elaine Lai-Han Leung, Xing-Xing Fan, Maria Pik Wong, Zhi-Hong Jiang, Zhong-Qiu Liu, Xiao-Jun Yao, Lin-Lin Lu, Yan-Ling Zhou 1, Li-Fong Yau, Vicky Pui-Chi Tin, Liang Liu. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation. *Antioxid Redox Signal*. 2016 Feb 10;24(5):263-79. IF=7.413.

(20) Zhong-Wen Yuan, Elaine Lai-Han Leung, Xing-Xing Fan, Hua Zhou, Liang Liu, Ying Xie. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC-MS/MS. *Talanta*. 2015 Nov 1; 144:20-8. IF=3.325.

## 6. 專利

(1) A novel treatment of Gefitinib-resistant non-small-cell lung cancer using sanguinarine. Leung EL, **Fan XX**, Liu L. (US patent provisional filed; Australia patent awarded for 8 years-2014100435)

(2) The new application of an alkaloid derived from a Chinese herbal for treatment of cancer by inhibiting cholesterol synthesis and fatty acid oxidation. Leung EL, **Fan XX**, Liu L, Wu JL. (US patent provisional filed; Australia patent awarded for 8 years-2014100831)

(3) Methods for Novel Drug Discovery, Treatment and Selective Targeting for Gefitinib-Resistant Non-Small-Cell Lung Cancer Harboring T790M Mutation. Leung EL, Liu L and **Fan XX** (US patent awarded-US 9439898 B2; Australia patent awarded for 8 years-2014100614)

(4) The application of (Z)3,4,5,4'-tetramethoxystilbene (TMS) in Gefitinib-resistant non-small-cell lung cancer cells. Leung EL, **Fan XX**, Liu L and Jiang ZB (US patent provisional filed; Australia patent awarded for 8 years-2015100187)

(5) Hydroxynaphthoquinone compounds (shikonin) for treating of non-small cell lung cancer. Liu L, Leung EL, Li X, **Fan XX** (US patent filed; Australia patent awarded for 8 year-2016100891)

## 7. 獎勵

(1) 2021 中银学术研究优秀奖

(2) 2018 教育部自然科学一等奖

(3) 2017 中珠生命科学研究二等奖